{"id":63639,"date":"2026-04-21T20:14:24","date_gmt":"2026-04-21T12:14:24","guid":{"rendered":"https:\/\/flcube.com\/?p=63639"},"modified":"2026-04-21T20:14:28","modified_gmt":"2026-04-21T12:14:28","slug":"biogen-completes-global-consolidation-of-felzartamab-with-100m-upfront-deal-for-greater-china-rights-from-tj-biopharma","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63639","title":{"rendered":"Biogen Completes Global Consolidation of Felzartamab with $100M Upfront Deal for Greater China Rights from TJ Biopharma"},"content":{"rendered":"\n<p><strong>Biogen Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/BIIB:NASDAQ\">NASDAQ: BIIB<\/a>) has finalized an agreement with <strong>TJ Biopharma<\/strong>, a China-based biopharmaceutical company, to acquire <strong>exclusive rights to felzartamab<\/strong>\u2014a <strong>CD38-targeting monoclonal antibody<\/strong>\u2014in <strong>Greater China<\/strong>. The transaction marks the <strong>final step in Biogen\u2019s consolidation of global ownership<\/strong> of the asset, resolving a multi-layered chain of prior licensing arrangements.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-terms-amp-financial-structure\">Deal Terms &amp; Financial Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Upfront Payment<\/strong><\/td><td><strong>$100 million<\/strong> (to be recorded as IPR&amp;D expense in Q2 2026)<\/td><\/tr><tr><td><strong>Milestone Payments<\/strong><\/td><td>Up to <strong>$750 million<\/strong> tied to development, regulatory, and commercial achievements<\/td><\/tr><tr><td><strong>Royalties<\/strong><\/td><td><strong>Mid-single-digit to low-double-digit<\/strong> tiered percentages on net sales in Greater China<\/td><\/tr><tr><td><strong>Assumed Obligations<\/strong><\/td><td>Biogen will also assume <strong>milestone and royalty commitments<\/strong> originally owed by MorphoSys to its partners under prior agreements<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-asset-history-amp-rights-consolidation\">Asset History &amp; Rights Consolidation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Origin<\/strong>: Felzartamab was discovered and initially developed by <strong>MorphoSys AG<\/strong> (acquired by <strong>Novartis<\/strong> in 2022)<\/li>\n\n\n\n<li><strong>Nov 2017<\/strong>: <strong>TJ Biopharma<\/strong> licensed <strong>Greater China rights<\/strong><\/li>\n\n\n\n<li><strong>Jun 2022<\/strong>: MorphoSys granted <strong>ex-China rights<\/strong> to <strong>HiBio<\/strong><\/li>\n\n\n\n<li><strong>May 2024<\/strong>: <strong>Biogen acquired HiBio for $1.8 billion<\/strong>, gaining all rights <strong>outside Greater China<\/strong><\/li>\n\n\n\n<li><strong>Apr 2026<\/strong>: Acquisition of <strong>Greater China rights<\/strong> from TJ Biopharma completes <strong>100% global control<\/strong><\/li>\n<\/ul>\n\n\n\n<p>This strategic closure eliminates future royalty leakage and streamlines development, manufacturing, and commercialization under a single sponsor\u2014critical for lifecycle management and partnership negotiations.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale\">Strategic Rationale<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Portfolio Synergy<\/strong>: Felzartamab complements Biogen\u2019s growing <strong>immunology and hematology pipeline<\/strong>, particularly in <strong>autoimmune and plasma cell disorders<\/strong><\/li>\n\n\n\n<li><strong>Global Development Efficiency<\/strong>: Unified control enables harmonized clinical trials, regulatory filings, and supply chain operations<\/li>\n\n\n\n<li><strong>Monetization Flexibility<\/strong>: Full ownership enhances optionality for <strong>co-development or out-licensing<\/strong> in non-core markets<\/li>\n<\/ul>\n\n\n\n<p>Felzartamab is currently in Phase II trials for <strong>IgG4-related disease<\/strong> and <strong>primary membranous nephropathy<\/strong>, with potential expansion into <strong>multiple myeloma<\/strong> and other CD38-expressing conditions.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context\">Market Context<\/h2>\n\n\n\n<p>The deal reflects a broader trend of <strong>Western biotechs repatriating global rights<\/strong> to high-value assets originally out-licensed during capital-constrained phases. For TJ Biopharma, the upfront provides non-dilutive funding to advance its internal pipeline, including oncology and metabolic programs.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding financial impact, development plans, and strategic benefits. Actual results may vary due to clinical outcomes, regulatory decisions, and market dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Biogen Inc. (NASDAQ: BIIB) has finalized an agreement with TJ Biopharma, a China-based biopharmaceutical company,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[351,16,993,527],"class_list":["post-63639","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-biogen","tag-cancer","tag-nasdaq-biib","tag-tj-biopharma"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Biogen Completes Global Consolidation of Felzartamab with $100M Upfront Deal for Greater China Rights from TJ Biopharma - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Biogen Inc. (NASDAQ: BIIB) has finalized an agreement with TJ Biopharma, a China-based biopharmaceutical company, to acquire exclusive rights to felzartamab\u2014a CD38-targeting monoclonal antibody\u2014in Greater China. The transaction marks the final step in Biogen\u2019s consolidation of global ownership of the asset, resolving a multi-layered chain of prior licensing arrangements.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=63639\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biogen Completes Global Consolidation of Felzartamab with $100M Upfront Deal for Greater China Rights from TJ Biopharma\" \/>\n<meta property=\"og:description\" content=\"Biogen Inc. (NASDAQ: BIIB) has finalized an agreement with TJ Biopharma, a China-based biopharmaceutical company, to acquire exclusive rights to felzartamab\u2014a CD38-targeting monoclonal antibody\u2014in Greater China. The transaction marks the final step in Biogen\u2019s consolidation of global ownership of the asset, resolving a multi-layered chain of prior licensing arrangements.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=63639\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-21T12:14:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-21T12:14:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63639#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63639\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Biogen Completes Global Consolidation of Felzartamab with $100M Upfront Deal for Greater China Rights from TJ Biopharma\",\"datePublished\":\"2026-04-21T12:14:24+00:00\",\"dateModified\":\"2026-04-21T12:14:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63639\"},\"wordCount\":362,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Biogen\",\"Cancer\",\"NASDAQ: BIIB\",\"TJ Biopharma\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63639#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63639\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=63639\",\"name\":\"Biogen Completes Global Consolidation of Felzartamab with $100M Upfront Deal for Greater China Rights from TJ Biopharma - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-21T12:14:24+00:00\",\"dateModified\":\"2026-04-21T12:14:28+00:00\",\"description\":\"Biogen Inc. (NASDAQ: BIIB) has finalized an agreement with TJ Biopharma, a China-based biopharmaceutical company, to acquire exclusive rights to felzartamab\u2014a CD38-targeting monoclonal antibody\u2014in Greater China. The transaction marks the final step in Biogen\u2019s consolidation of global ownership of the asset, resolving a multi-layered chain of prior licensing arrangements.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63639#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63639\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63639#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biogen Completes Global Consolidation of Felzartamab with $100M Upfront Deal for Greater China Rights from TJ Biopharma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Biogen Completes Global Consolidation of Felzartamab with $100M Upfront Deal for Greater China Rights from TJ Biopharma - Insight, China&#039;s Pharmaceutical Industry","description":"Biogen Inc. (NASDAQ: BIIB) has finalized an agreement with TJ Biopharma, a China-based biopharmaceutical company, to acquire exclusive rights to felzartamab\u2014a CD38-targeting monoclonal antibody\u2014in Greater China. The transaction marks the final step in Biogen\u2019s consolidation of global ownership of the asset, resolving a multi-layered chain of prior licensing arrangements.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=63639","og_locale":"en_US","og_type":"article","og_title":"Biogen Completes Global Consolidation of Felzartamab with $100M Upfront Deal for Greater China Rights from TJ Biopharma","og_description":"Biogen Inc. (NASDAQ: BIIB) has finalized an agreement with TJ Biopharma, a China-based biopharmaceutical company, to acquire exclusive rights to felzartamab\u2014a CD38-targeting monoclonal antibody\u2014in Greater China. The transaction marks the final step in Biogen\u2019s consolidation of global ownership of the asset, resolving a multi-layered chain of prior licensing arrangements.","og_url":"https:\/\/flcube.com\/?p=63639","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-21T12:14:24+00:00","article_modified_time":"2026-04-21T12:14:28+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=63639#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=63639"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Biogen Completes Global Consolidation of Felzartamab with $100M Upfront Deal for Greater China Rights from TJ Biopharma","datePublished":"2026-04-21T12:14:24+00:00","dateModified":"2026-04-21T12:14:28+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=63639"},"wordCount":362,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Biogen","Cancer","NASDAQ: BIIB","TJ Biopharma"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=63639#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=63639","url":"https:\/\/flcube.com\/?p=63639","name":"Biogen Completes Global Consolidation of Felzartamab with $100M Upfront Deal for Greater China Rights from TJ Biopharma - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-21T12:14:24+00:00","dateModified":"2026-04-21T12:14:28+00:00","description":"Biogen Inc. (NASDAQ: BIIB) has finalized an agreement with TJ Biopharma, a China-based biopharmaceutical company, to acquire exclusive rights to felzartamab\u2014a CD38-targeting monoclonal antibody\u2014in Greater China. The transaction marks the final step in Biogen\u2019s consolidation of global ownership of the asset, resolving a multi-layered chain of prior licensing arrangements.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=63639#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=63639"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=63639#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Biogen Completes Global Consolidation of Felzartamab with $100M Upfront Deal for Greater China Rights from TJ Biopharma"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63639","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=63639"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63639\/revisions"}],"predecessor-version":[{"id":63641,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63639\/revisions\/63641"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=63639"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=63639"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=63639"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}